Epidemiology and treatment of antimicrobialresistant gram-negative bacteria in Korea

키워드

참고문헌 (50)

1. Martin-Loeches I, "Risks for multidrug-resistant pathogens in the ICU", Curr Opin Crit Care, 20, pp.516~524 (2014)[DOI]
2. Yoon YK, "Trends of antibiotic consumption in Korea according to national reimbursement data (2008-2012): a population- based epidemiologic study", Medicine (Baltimore), 94, pp.e2100~ (2015)[DOI]
3. Kim DS, "Epidemiologic investigation on antibiotic use using defined daily dose", J Korean Acad Manag Care Pharm, 2, pp.47~59 (2010)
4. Yangsoon Lee, "Recent Trends in Antimicrobial Resistance in Intensive Care Units in Korea", Korean Journal of Nosocomial Infection Control, 19(1), pp.29~ (2014), Korean Society for Nosocomial Infection Control (KAMJE)[DOI]
5. Abbasi J, "Infectious disease expert sees threat from colistin- resistant superbug", JAMA, 316, pp.806~807 (2016)[DOI]
6. Ryu S, "The new Korean action plan for containment of antimicrobial resistance", J Glob Antimicrob Resist, 8, pp.70~73 (2017)[DOI]
7. 김도균, "Increasing Resistance to Extended-Spectrum Cephalosporins, Fluoroquinolone, and Carbapenem in Gram-Negative Bacilli and the Emergence of Carbapenem Non-Susceptibility in Klebsiella pneumoniae: Analysis of Korean Antimicrobial Resistance Monitoring System (KARMS) Data From 2013 to 2015", Annals of Laboratory Medicine, 37(3), pp.231~239 (2017), 대한진단검사의학회
8. Cai Y, "Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies", J Antimicrob Chemother, 67, pp.1607~1615 (2012)[DOI]
9. Kim EJ, "Trends of device utilization ratios in intensive care units over 10-year period in South Korea: device utilization ratio as a new aspect of surveillance", J Hosp Infect (2017)
10. 정윤섭, "Increase in the Prevalence of Carbapenem-Resistant Acinetobacter Isolates and Ampicillin-Resistant Non- Typhoidal Salmonella Species", Infection and Chemotherapy, 46(2), pp.84~93 (2014), 대한감염학회
11. [URL]
12. Jasemi S, "Trend of extensively drug-resistant Acinetobacter baumannii and the remaining therapeutic options: a multicenter study in Tehran, Iran over a 3-year period", Lett Appl Microbiol, 63, pp.466~472 (2016)[DOI]
13. Moon SY, "Clinical experience of tigecycline treatment in infections caused by extensively drug-resistant Acinetobacter spp", Microb Drug Resist, 18, pp.562~566 (2012)[DOI]
14. Johnson JR, "Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States", Clin Infect Dis, 51, pp.286~294 (2010)[DOI]
15. Rogers BA, "Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain", J Antimicrob Chemother, 66, pp.1~14 (2011)[DOI]
16. Kim SY, "Prevalence and characteristics of Escherichia coli sequence type 131 and its H30 and H30Rx subclones: a multicenter study from Korea", Diagn Microbiol Infect Dis, 84, pp.97~101 (2016)[DOI]
17. Kim H, "Risk factors and molecular features of sequence type (ST) 131 extended-spectrum <TEX>${\beta}$<", TEX>-lactamase-producing Escherichia coli in community-onset bacteremia, 2017, pp.7, 14640~
18. Kim YA, "Community-onset extended- spectrum-<TEX>${\beta}$<", TEX>-lactamase-producing Escherichia coli sequence type 131 at two Korean community hospitals: the spread of multidrug-resistant E. coli to the community via healthcare facilities, 2017, pp.54, 39~42
19. Johnson JR, "Abrupt emergence of a single dominant multidrug-resistant strain of Escherichia coli", J Infect Dis, 207, pp.919~928 (2013)[DOI]
20. DSouza R, "Molecular epidemiology and resistome analysis of multidrug-resistant ST11 Klebsiella pneumoniae strain containing multiple copies of extended-spectrum <TEX>${\beta}$<", TEX>-lactamase genes using whole-genome sequencing, 2017, pp.40, 38~44
21. Wachino J, "Exogenously acquired 16S rRNA methyltransferases found in aminoglycoside-resistant pathogenic Gram-negative bacteria: an update", Drug Resist Updat, 15, pp.133~148 (2012)[DOI]
22. Pfeifer Y, "Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens", Int J Med Microbiol, 300, pp.371~379 (2010)[DOI]
23. Bauernfeind A, "Extended broad spectrum beta-lactamase in Klebsiella pneumoniae including resistance to cephamycins", Infection, 17, pp.316~321 (1989)[DOI]
24. Queenan AM, "Carbapenemases: the versatile beta-lactamases", Clin Microbiol Rev, 20, pp.440~458 (2007)[DOI]
25. Bonomo RA, "Carbapenemase- producing organisms: a global scourge!", Clin Infect Dis (2017)
26. 이효진, "Carbapenem-resistant Enterobacteriaceae: Prevalence and Risk Factors in a Single Community-Based Hospital in Korea", Infection and Chemotherapy, 48(3), pp.166~173 (2016), 대한감염학회
27. Kim MN, "Nosocomial clustering of NDM-1-producing Klebsiella pneumoniae sequence type 340 strains in four patients at a South Korean tertiary care hospital", J Clin Microbiol, 50, pp.1433~1436 (2012)[DOI]
28. Jeong SH, "Clonal and horizontal spread of the blaOXA-232 gene among Enterobacteriaceae in a Korean hospital", Diagn Microbiol Infect Dis, 82, pp.70~72 (2015)[DOI]
29. Hong SK, "First outbreak of KPC-2-producing Klebsiella pneumoniae sequence type 258 in a hospital in South Korea", J Clin Microbiol, 51, pp.3877~3879 (2013)[DOI]
30. 김영아, "Abrupt Increase in Rate of Imipenem Resistance in Acinetobacter baumannii Complex Strains Isolated from General Hospitals in Korea and Correlation With Carbapenem Administration During 2002–2013", Annals of Laboratory Medicine, 38(2), pp.179~181 (2018), 대한진단검사의학회[DOI]
31. Lee Y, "Increasing prevalence of bla- OXA-23-carrying Acinetobacter baumannii and the emergence of blaOXA-182-carrying Acinetobacter nosocomialis in Korea", Diagn Microbiol Infect Dis, 77, pp.160~163 (2013)[DOI]
32. Doi Y, "Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options", Semin Respir Crit Care Med, 36, pp.85~98 (2015)[DOI]
33. Lee K, "bla(VIM-2) cassette-containing novel integrons in metallo-beta-lactamase-producing Pseudomonas aeruginosa and Pseudomonas putida isolates disseminated in a Korean hospital", Antimicrob Agents Chemother, 46, pp.1053~1058 (2002)[DOI]
34. 홍덕진, "Epidemiology and Characteristics of Metallo-β-Lactamase-Producing Pseudomonas aeruginosa", Infection and Chemotherapy, 47(2), pp.81~97 (2015), 대한감염학회[DOI]
35. 김영아, "Correlation of Aminoglycoside Consumption and Amikacin- or Gentamicin-Resistant Pseudomonas aeruginosa in Long-Term Nationwide Analysis: Is Antibiotic Cycling an Effective Policy for Reducing Antimicrobial Resistance?", Annals of Laboratory Medicine, 38(2), pp.176~178 (2018), 대한진단검사의학회[DOI]
36. Almaghrabi R, "Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents", Antimicrob Agents Chemother, 58, pp.4443~4451 (2014)[DOI]
37. Lemos EV, "Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis", Clin Microbiol Infect, 20, pp.416~423 (2014)[DOI]
38. Lee NY, "Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia", Infect Control Hosp Epidemiol, 28, pp.713~719 (2007)[DOI]
39. 이호진, "Clinical and Economic Evaluation of Multidrug-Resistant Acinetobacter baumannii Colonization in the Intensive Care Unit", Infection and Chemotherapy, 48(3), pp.174~180 (2016), 대한감염학회
40. Batirel A, "Comparison of colistin- carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections", Eur J Clin Microbiol Infect Dis, 33, pp.1311~1322 (2014)[DOI]
41. Shields RK, "Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients", PLoS One, 7, pp.e52349~ (2012)[DOI]
42. Tzouvelekis LS, "Treating infections caused by carbapenemase- producing Enterobacteriaceae", Clin Microbiol Infect, 20, pp.862~872 (2014)[DOI]
43. Falagas ME, "Antibiotic treatment of infections due to carbapenem- resistant Enterobacteriaceae: systematic evaluation of the available evidence", Antimicrob Agents Chemother, 58, pp.654~663 (2014)[DOI]
44. Falagas ME, "Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections", Clin Infect Dis, 40, pp.1333~1341 (2005)[DOI]
45. Nation RL, "Colistin and polymyxin B: peas in a pod, or chalk and cheese?", Clin Infect Dis, 59, pp.88~94 (2014)[DOI]
46. Kassamali Z, "To B or not to B, that is the question: is it time to replace colistin with polymyxin B?", Pharmacotherapy, 35, pp.17~21 (2015)[DOI]
47. Roberts JA, "Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution", J Antimicrob Chemother, 64, pp.142~150 (2009)[DOI]
48. MacVane SH, "Prolonging <TEX>${\beta}$<", TEX>-lactam infusion: a review of the rationale and evidence, and guidance for implementation, 2014, pp.43, 105~113
49. Qureshi ZA, "Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens", Antimicrob Agents Chemother, 56, pp.2108~2113 (2012)[DOI]
50. Lopez-Cortes LE, "Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort", J Antimicrob Chemother, 69, pp.3119~3126 (2014)[DOI]

관련 논문AI추천